ALN-CIDEB

PreclinicalSmall molecule

ALN-CIDEB is one of 2 small molecule programs targeting Metabolic Dysfunction-Associated Steatotic Liver Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metabolic Dysfunction-Associated Steatotic Liver DiseaseRecruiting

Metabolic Dysfunction-Associated Steatotic Liver DiseasePreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Metabolic Dysfunction-Associated Steatotic Liver Disease

#DrugCompanyPhaseTrials

Iglarlixi

Sanofi

Phase 3

1 2

ALN-CIDEB

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT06836609

Clinical

Trials by Indication[1]

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Two Doses of ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting· Regeneron logo

Regeneron·Preclinical·NCT06836609·132 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALN-CIDEB. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALN-CIDEB compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALN-CIDEB. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Regeneron

ALN-CIDEB

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Metabolic Dysfunction-Associated Steatotic Liver Disease1 trial

References

Drug Info

Quick Facts

Related News